Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The PI3K/AKT/mTOR pathway is frequently altered and hyperactivated in various cancers, regulating cell growth, survival, and metastasis.
• Metastatic bladder cancer (BLCA) has limited therapeutic options, despite known molecular alterations in the PI3K/AKT/mTOR pathway.

Purpose of the Study:

• To review preclinical and clinical studies of PI3K pathway inhibitors in BLCA.
• To identify technical challenges contributing to contradictory findings in preclinical PI3K inhibitor studies.
• To address obstacles for optimizing PI3K inhibition in BLCA and its clinical translation.

Main Methods:

• Literature review of preclinical studies and clinical trials involving PI3K pathway inhibitors in BLCA.
• Analysis of published data focusing on technical challenges and optimization strategies.
• Synthesis of findings to guide future research and clinical application.

Main Results:

• PI3K pathway inhibitors have been investigated in BLCA, but clinical trials have not yet met their endpoints.
• Technical challenges in preclinical studies may lead to inconsistent results regarding PI3K pathway inhibition efficacy.
• Specific challenges in optimizing PI3K inhibition for BLCA require further investigation.

Conclusions:

• Despite the rationale for targeting the PI3K/AKT/mTOR pathway in BLCA, clinical success has been limited.
• Addressing technical and translational challenges is essential for effective PI3K inhibition in BLCA.
• Further research is needed to overcome barriers and enable successful clinical application of PI3K inhibitors for BLCA patients.